JP2006510582A5 - - Google Patents

Download PDF

Info

Publication number
JP2006510582A5
JP2006510582A5 JP2004529835A JP2004529835A JP2006510582A5 JP 2006510582 A5 JP2006510582 A5 JP 2006510582A5 JP 2004529835 A JP2004529835 A JP 2004529835A JP 2004529835 A JP2004529835 A JP 2004529835A JP 2006510582 A5 JP2006510582 A5 JP 2006510582A5
Authority
JP
Japan
Prior art keywords
group
optionally substituted
alkyl
amino
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004529835A
Other languages
English (en)
Japanese (ja)
Other versions
JP4494205B2 (ja
JP2006510582A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/026317 external-priority patent/WO2004017908A2/en
Publication of JP2006510582A publication Critical patent/JP2006510582A/ja
Publication of JP2006510582A5 publication Critical patent/JP2006510582A5/ja
Application granted granted Critical
Publication of JP4494205B2 publication Critical patent/JP4494205B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2004529835A 2002-08-26 2003-08-21 カルシウム受容体調節化合物およびその用途 Expired - Lifetime JP4494205B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40601202P 2002-08-26 2002-08-26
US46612903P 2003-04-28 2003-04-28
PCT/US2003/026317 WO2004017908A2 (en) 2002-08-26 2003-08-21 Calcium receptor modulating compound and use thereof

Publications (3)

Publication Number Publication Date
JP2006510582A JP2006510582A (ja) 2006-03-30
JP2006510582A5 true JP2006510582A5 (enExample) 2008-09-04
JP4494205B2 JP4494205B2 (ja) 2010-06-30

Family

ID=31949909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004529835A Expired - Lifetime JP4494205B2 (ja) 2002-08-26 2003-08-21 カルシウム受容体調節化合物およびその用途

Country Status (12)

Country Link
US (3) US7514441B2 (enExample)
EP (1) EP1572113B1 (enExample)
JP (1) JP4494205B2 (enExample)
KR (1) KR101050700B1 (enExample)
AU (1) AU2003265585B2 (enExample)
BR (1) BRPI0313880B8 (enExample)
CA (1) CA2494700C (enExample)
ES (1) ES2635838T3 (enExample)
NO (1) NO332991B1 (enExample)
NZ (1) NZ538223A (enExample)
PL (1) PL382706A1 (enExample)
WO (1) WO2004017908A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265585B2 (en) 2002-08-26 2008-07-03 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7361789B1 (en) 2004-07-28 2008-04-22 Amgen Inc. Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US20090304821A1 (en) * 2006-03-08 2009-12-10 Takeda Pharmaceutical Company Limited Pharmaceutical Combination
EA200802166A1 (ru) 2006-04-20 2009-06-30 Эмджен Инк. Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
CA2681582C (en) 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
ES2499015T3 (es) * 2007-05-08 2014-09-26 Ajinomoto Co., Inc. Agente profiláctico o terapéutico para la diarrea
UA103006C2 (ru) 2007-08-27 2013-09-10 Басф Се Пиразольные соединения для борьбы с бесхребетными вредителями
WO2009051244A1 (ja) * 2007-10-18 2009-04-23 Takeda Pharmaceutical Company Limited 複素環化合物
EP2292592B1 (en) 2008-06-05 2012-09-05 Asahi Kasei Pharma Corporation Sulfonamide compound and application thereof
BRPI0914779A2 (pt) * 2008-06-16 2015-10-20 Hoffmann La Roche derivados de pirrolidina como antagonistas de receptor de nk2
KR101364869B1 (ko) 2008-09-24 2014-02-21 바스프 에스이 무척추　해충을　방제하기　위한　피라졸　화합물
BRPI0919085B1 (pt) * 2008-09-24 2021-05-11 Basf Se métodos não terapêuticos para controlar pragas invertebradas e para proteger material de propagação de plantas e/ou plantas que se desenvolvem dos mesmos, compostos de pirazol ou um sal ou um n-óxido dos mesmos, e, composição agrícola
WO2010096115A1 (en) 2008-10-29 2010-08-26 Apath, Llc Compounds, compositions and methods for control of hepatitis c viral infections
US8318759B2 (en) * 2009-02-18 2012-11-27 Hoffmann-La Roche Inc. Pyrrolidine derivatives as NK3 receptor antagonists
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
CN102471330A (zh) 2009-07-06 2012-05-23 巴斯夫欧洲公司 用于防治无脊椎动物害虫的哒嗪化合物
CN102471321A (zh) 2009-07-06 2012-05-23 巴斯夫欧洲公司 用于防治无脊椎动物害虫的哒嗪化合物
WO2011009804A2 (en) 2009-07-24 2011-01-27 Basf Se Pyridine derivatives compounds for controlling invertebrate pests
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US20140038989A1 (en) * 2011-04-20 2014-02-06 Glaxo Group Limited Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
AU2013344716B2 (en) 2012-11-16 2018-03-01 University Health Network Pyrazolopyrimidine compounds
US10035801B2 (en) 2013-03-13 2018-07-31 Genentech, Inc. Pyrazolo compounds and uses thereof
BR112015025260B1 (pt) * 2013-04-25 2021-11-03 Beigene, Ltd Compostos heterocíclicos fundidos como inibidores da proteína quinase, sua composição, combinação e uso
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
RS63571B9 (sr) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva
AU2015238298B2 (en) 2014-03-27 2019-04-18 Janssen Pharmaceutica Nv Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors
EA032255B1 (ru) 2014-03-27 2019-04-30 Янссен Фармацевтика Нв ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИНА И ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРО-4H-ПИРАЗОЛО[1,5-a][1,4]ДИАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Ros1
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
US10316040B2 (en) 2015-10-16 2019-06-11 Eisai R&D Management Co., Ltd. EP4 antagonists
EP3395344B1 (en) * 2015-12-25 2022-03-16 Takeda Pharmaceutical Company Limited Medicine for treating heart failure
CN118340787A (zh) * 2016-03-28 2024-07-16 武田药品工业株式会社 药物
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
JP7402685B2 (ja) 2016-08-16 2023-12-21 ベイジーン スウィッツァーランド ゲーエムベーハー （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用
AU2017313085B2 (en) 2016-08-19 2024-06-20 Beone Medicines I Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
AU2017319500C1 (en) 2016-08-31 2022-10-20 Les Laboratoires Servier Inhibitors of cellular metabolic processes
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
AR110282A1 (es) 2016-12-02 2019-03-13 Hoffmann La Roche Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
CN110461847B (zh) 2017-01-25 2022-06-07 百济神州有限公司 (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
WO2018199235A1 (ja) * 2017-04-27 2018-11-01 武田薬品工業株式会社 複素環化合物
AU2018257332B2 (en) * 2017-04-27 2021-11-04 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2019001417A1 (en) 2017-06-26 2019-01-03 Beigene, Ltd. IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA
CA3185865A1 (en) 2017-07-14 2019-01-17 F. Hoffmann-La Roche Ag Bicyclic ketone compounds and methods of use thereof
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
KR20200083515A (ko) 2017-10-31 2020-07-08 에프. 호프만-라 로슈 아게 2고리 설폰 및 설폭사이드, 및 이의 사용 방법
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
JP7585205B2 (ja) 2019-01-11 2024-11-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二環式ピロロトリアゾールケトン化合物及びその使用方法
WO2020249001A1 (zh) 2019-06-10 2020-12-17 百济神州瑞士有限责任公司 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918074A (en) * 1984-03-12 1990-04-17 Yoshitomi Pharmaceutical Industries, Ltd. Polyazaheterocycle compounds
EP0217142A3 (en) 1985-09-30 1988-01-07 Yoshitomi Pharmaceutical Industries, Ltd. A polyazaheterocyclic compound
US4746656A (en) * 1986-07-21 1988-05-24 E. R. Squibb & Sons, Inc. 1,2,4,7-tetrahydro-2-oxopyrazolo[1,5-a]pyrimidine derivatives
GB9303993D0 (en) * 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
ES2222919T3 (es) 1999-08-27 2005-02-16 Abbott Laboratories Compuestos sulfonilfenilpirazoles utiles como inhibidores de cox-2.
CN1891699A (zh) * 2000-01-24 2007-01-10 基纳西亚股份有限公司 用于治疗的吗啉代基取代的化合物
NZ528639A (en) * 2001-03-14 2005-07-29 Gruenenthal Chemie Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics
AU2003265585B2 (en) * 2002-08-26 2008-07-03 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof

Similar Documents

Publication Publication Date Title
JP2006510582A5 (enExample)
AU2020341681B2 (en) RIP1 inhibitory compounds and methods for making and using the same
AU2020341708B2 (en) RIP1 inhibitory compounds and methods for making and using the same
KR102808215B1 (ko) Rip1 억제 화합물 및 이를 제조하고 사용하는 방법
KR102824962B1 (ko) 헤테로시클릭 rip1 억제 화합물
RU2305682C2 (ru) Производные 4-амино-5-фенил-7- циклобутилпирроло[2,3-d]пиримидина
ES2461967T3 (es) Compuestos de pirrolo[2,3-d]pirimidina
ES2302949T3 (es) Pirrolopirimidina y derivados de pirrolopirimidina sustituidos con un grupo amino ciclico.
BRPI0819719B1 (pt) Compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo
JP2018532759A (ja) ピリミジン誘導体及びその使用
JP2022529311A (ja) Ｔｙｋ２偽キナーゼリガンド
JP2017533205A (ja) ｍＩＤＨ１阻害剤としてのベンゾイミダゾール−２−アミン
JPH10510536A (ja) ２−置換された１，２，５−チアジアゾリジン−３−オン１，１−ジオキシド及びそれらの組成物
JP2025013995A (ja) Ｒｉｐ１ｋ阻害剤
WO2004113345A1 (ja) 縮合ピロール化合物及びその医薬用途
JP2025156455A (ja) チアゾロ［５，４－ｂ］ピリジンＭＡＬＴ－１阻害剤
JP5995841B2 (ja) ３，４−ジヒドロピロロ［１，２−ａ］ピラジン−２，８（１Ｈ）−ジカルボキサミド誘導体、その調製、およびその治療的使用
AU2017326297B2 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
RS51912B (sr) DERIVATI 1,2,3,4-TETRAHIDROPIROLO(1,2-a)PIRAZIN-6-KARBOKSAMIDA I 2,3,4,5-TETRAHIDROPIROLO(1,2-a)(1,4)-DIAZEPIN-7-KARBOKSAMIDA NJIHOVO DOBIJANJE I TERAPEUTSKA PRIMENA
JPS61282382A (ja) フエニル置換１，８−ナフチリジン誘導体、そのエステルおよびその塩
EA047748B1 (ru) Гетероциклические соединения, ингибирующие rip1
EA048929B1 (ru) Соединения, ингибирующие rip1, и способы их получения и применения
JP2013507340A (ja) ミクログリア活性化の阻害剤としてのピロロ［３，２−ｅ］［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体
JPWO1995008542A1 (ja) ファルネシルトランスフェラーゼ阻害剤